DefiniGEN

Drug Discovery Innovation Programme (DDIP) is only a few days away! Our CBO, Heidi Kingdon Jones and Director of Business Development, NA, French Lewis, III will be in attendance and ready to answer all your questions about how our iPSC-derived Hepatocytes can overcome the drawbacks of primary cells. You can read our article, "Redefining in vitro Drug Testing" on DDIP's website right now to learn more: https://lnkd.in/eXJzcVAX We look forward to joining you for two days of ground-breaking insights, networking and collaboration. #liver #stemcells #ipscs #industryblog #Biotech #drugdiscovery #drugdiscoveryconference2025 #ddip2025 #liverdisease #diseasemodel

Unlock the Power of Precision Gene Editing with DefiniGEN 🔬 Looking to accelerate your research with cutting-edge genome editing? DefiniGEN's expert-driven services are here to deliver results tailored to your needs. From permanent or conditional knock-outs, to point mutations and targeted insertions, we specialize in precise genetic modifications that empower ground-breaking discoveries. Why work with us? ✔ Unmatched Expertise: With years of experience handling iPSCs, we have a deep understanding of CRISPR-based genome editing. ✔ High Success Rates: Our proven methodologies ensure reliability and precision. ✔ Collaborative Approach: We partner closely with you to align every step with your research objectives. Whether you're driving innovation in drug development, disease modeling, or regenerative medicine, our genome editing services are designed to accelerate your progress. Ready to take your projects to the next level? Learn more about our services here: https://lnkd.in/dZP-_hty #GeneEditing #CRISPR #iPSC #GenomeEngineering #DrugDevelopment #liver #hepatocytes #liverdisease #stemcells

We're excited to be attending Drug Discovery Innovation Programme (DDIP) in San Diego on 3rd March! If you're attending and would like to learn more about our iPSC-derived hepatocytes and disease models, speak to our CBO, Heidi Kingdon Jones and Director of Business Development, North America, French Lewis, III who will be in attendance. In the meantime check out how our cells are redefining drug discovery in the blog linked below

🚀 Overcoming the Bottleneck in Drug Discovery 🧬 One of the biggest challenges in drug development? Unreliable preclinical models. Traditional 2D cultures and animal testing often fail to predict human drug metabolism, leading to high clinical trial failure rates and wasted resources. This is where our iPSC-derived hepatocytes, Opti-HEP, come in. Opti-HEP offers: ✅ Human-relevant liver function for better drug metabolism & toxicity predictions ✅ Scalability for high-throughput screening without donor variability ✅ Extended viability—lasting weeks instead of days for long-term studies ✅ Patient-specific disease modeling to improve efficacy testing By integrating Opti-HEP into drug discovery, researchers can significantly reduce failures, accelerate timelines, and enhance patient safety. 📖 Read more about how Opti-HEP is transforming preclinical testing: https://lnkd.in/ef9sAF6g #DrugDiscovery #iPSC #Biotech #PreclinicalTesting #Hepatocytes #PharmaInnovation #liver #liverdisease #stemcells

DefiniGEN is excited to announce our participation in the upcoming ELRIG German Forum: Target Innovation & Novel Screening Technologies ⏰ February 18, 2025 🌍 VKU Forum, Berlin The forum will focus on pioneering therapeutic targets and the latest methodologies propelling advancements in drug discovery through cutting-edge approaches and technological innovations that are expanding the tractable target space. At DefiniGEN, we specialize in providing human-relevant, induced pluripotent stem cell (iPSC)-derived hepatocytes and disease models. Our solutions are designed to enhance the predictability and efficiency of drug discovery pipelines. We invite you to meet with our team, Ioannis Kasioulis and Malek Haddad to learn more about our offerings and discuss how our iPSC-derived models can accelerate your research. To schedule a meeting with our team during the forum, please contact us through our website here: https://lnkd.in/e9p-BzBi Join us in Berlin to explore the future of drug discovery and how DefiniGEN's innovative solutions can contribute to your success. #elrig #drugdiscovery #drugscreening #efficacyscreening #pharma #biotech #hepatocyes #liver #stemcells #iPSCs #liverdisease #masld

Collaboration is at the heart of all great scientific accomplishments. By working with Atelerix Ltd. we can now transport Opti-HEP and disease models by encapsulating them in Aterlerix’s hydrogel in 96-well plates under normoxic conditions. What this means for our clients: ✅ This innovation allows for the transport of plates over long distance for large-scale screening, efficacy and predictive toxicology studies. ✅ The live plate format removes the variation introduced by the cryopreservation and thawing process. ✅ Hydrogel-based encapsulation of cells shows comparable cell viability to non-encapsulated cells and comparable expression of hepatocyte maturity markers (ALB, A1AT and HNF4A). If you are in need of iPSC-derived hepatocytes and disease models, then we want to work with you. Check out our range of hepatic wild-type and disease models here: https://lnkd.in/e6fswPAn

Accelerate your research with DefiniGEN's Intestinal Organoids! Are you looking for advanced, physiologically relevant models to take your intestinal disease research or drug development to the next level? We offer high-quality human intestinal organoids derived from iPSCs, designed to provide predictive, scalable, and disease-relevant results. Why Choose our Intestinal Organoids? ✅ Precision and Relevance: Ideal for studying a wide range of intestinal diseases, including IBD, cancer, and infection. ✅ Drug Screening & Toxicology: Accelerate drug discovery with more reliable, human-relevant data. ✅ Customizable: Tailor your organoid models to specific research needs. Whether you're in academic research, biotech, or pharma, our intestinal organoids provide the cutting-edge technology you need to drive innovation in gastrointestinal health and therapeutic development. Learn more about our products and accelerate your research: https://lnkd.in/edmmXDrN #IntestinalOrganoids #OrganoidTechnology #BiomedicalResearch #DrugDiscovery #PharmaInnovation #IntestinalHealth #DefiniGEN #iPSCs #GastrointestinalResearch #stemcells

We are thrilled to announce that DefiniGEN has been featured in Nature Portfolio's Biopharma Dealmakers Journal, highlighting our innovative work in developing highly predictive in vitro liver disease models. Our platform generates induced pluripotent stem cell (iPSC)-derived hepatocytes, providing unparalleled predictivity for drug efficacy and toxicity studies. This recognition underscores our commitment to accelerating the development of effective treatments for life-threatening liver conditions. Read the full article here: https://lnkd.in/erJ334qi And learn more about our platform: https://lnkd.in/dsVg46U3 #DefiniGEN #BiopharmaDealmakers #LiverDisease #DrugDevelopment #iPSC #StemCells #Biotechnology #Pharmaceuticals #HealthcareInnovation #hepatocytes

🔬 Accelerate Drug Discovery with Predictive Efficacy Screening 🔬 Traditional animal models and primary cells often fail to translate effectively into human clinical outcomes. This translational gap slows down drug development and increases the risk of late-stage failures. At DefiniGEN, we provide iPSC-derived wild-type and disease models that offer highly predictive, physiologically relevant human systems for efficacy screening at scale. Our advanced in vitro platforms enable: ✅ More accurate disease modeling – reflecting human biology more closely than traditional models ✅ Enhanced translatability – reducing the risk of failure in clinical trials ✅ Scalable, reproducible testing – optimizing drug screening workflows From #MASLD, #A1ATD, and Urea Cycle Disorders to Wilson’s Disease and intestinal organoids, our models help de-risk drug development and accelerate the path to effective therapies. Discover how DefiniGEN can support your research: https://lnkd.in/e9U6MY6R #DrugDiscovery #EfficacyScreening #iPSC #TranslationalResearch #DiseaseModeling #CellTherapy #stemcells

🚨 Breaking Boundaries in Hepatocyte Functionality 🚨 Did you know that many iPSC-derived hepatocytes lack functional membrane localization and activity of the Asialoglycoprotein Receptor 1 (ASGR1)? This is a critical limitation, but DefiniGEN’s Opti-HEP has changed the game. Our Opti-HEP wild-type hepatocyte model demonstrates robust ASGR1 functionality, setting them apart from other iPSC-derived hepatocytes and even primary hepatocytes, which can only be cultured for up to a week. 💡 Why does this matter? ASGR1 plays a crucial role in hepatocyte-specific endocytosis and clearance processes. Without ASGR1 activity: ❌ Drug metabolism and toxicity studies can lack precision. ❌ Predictive modeling for Drug-Induced Liver Injury (DILI) becomes unreliable. ❌ This culminates in ineffective compounds being selected for clinical trials which go on to fail, costing you time and resources. With Opti-HEP, you can: ✅ Achieve unmatched predictive accuracy in toxicity testing. ✅ Gain confidence in DILI studies, thanks to durable and reproducible functionality. ✅ Optimize research workflows with hepatocytes that deliver consistent performance beyond a week in culture. 👉 Ready to elevate your research? Explore the full potential of Opti-HEP here: https://lnkd.in/dsVg46U3 #iPSC #Hepatocytes #ToxicityTesting #DILI #PharmaInnovation #stemcells #liverdisease #liver